Possible non-classic intracellular and molecular mechanisms of LDL cholesterol action contributing to the development and progression of atherosclerosis.
Elevated low density lipoprotein (LDL) cholesterol (LDL-C) levels represent one of the most important risk factors for atherosclerosis and therefore cardiovascular morbidity and mortality. LDL-C operates at different levels and through various classic and non-classic mechanisms. For example, it has been recently shown that both native and oxidized LDL are potent growth factors for several cell types such as vascular smooth muscle cells (VSMC) participating in the development and progression of atherosclerosis. Moreover, LDL-C modulates the expression of various growth factors and growth factor receptors that are involved in the process of atherosclerosis. More specifically, LDL-C can phosphorylate and therefore activate the epidermal growth factor (EGF) receptor and enhance the production of platelet derived growth factor (PDGF)-AA and of the PDGF receptors. LDL as well as oxidized LDL (oxLDL) signal transduction pathways involve trimeric G-proteins and cAMP, protein kinase C and ceramide, diacylglycerol and inositol-1,4,5-triphosphate, Ca(+2), Na(+)/H(+) exchange, c-fos and egr-1, phospholipases C, A2 and D, Raf-1, MEK1/2, the ERK1/2 (p42/44), SAP/JNK and p38 isoforms of the mitogen activated protein kinases (MAPK) as well as the signal transuding element gp 130. Furthermore, the mitogenic effects of oxLDL may be mediated by its oxidation products such as lysophosphatidylcholine (LPC), and lysophosphatidic acid (LPA), through LDL-induced lactosylceramide (LacCer) synthesis, and, as our group has recently shown, through LDL-adherent factors such as sphingosine-1-phosphate (S1P) and sphingosylphosphorylcholine (SPC). We review the various LDL-mediated signal transduction pathways implicated with the development and progression of atherosclerosis.
Gouni-Berthold
Ioanna
I
Department of Internal Medicine II, University of Cologne, Center for Molecular Medicine Cologne, Germany.
Sachinidis
Agapios
A
D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D008078:Cholesterol, LDL / Q000097:blood / Q000502:physiology*; D003324:Coronary Artery Disease / Q000097:blood*; D050822:Cytokine Receptor gp130; D019204:GTP-Binding Proteins / Q000378:metabolism; D006133:Growth Substances / Q000096:biosynthesis; D006801:Humans; D015544:Inositol 1,4,5-Trisphosphate / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000378:metabolism; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D010084:Oxidation-Reduction; D011493:Protein Kinase C / Q000378:metabolism; D017978:Receptors, Growth Factor / Q000096:biosynthesis; D015398:Signal Transduction / Q000502:physiology; D013107:Sphingolipids / Q000378:metabolism
D015703:Antigens, CD; D008078:Cholesterol, LDL; D006133:Growth Substances; C494199:IL6ST protein, human; D008562:Membrane Glycoproteins; D016328:NF-kappa B; D017978:Receptors, Growth Factor; D013107:Sphingolipids; D050822:Cytokine Receptor gp130; D015544:Inositol 1,4,5-Trisphosphate; D011493:Protein Kinase C; D020928:Mitogen-Activated Protein Kinases; D019204:GTP-Binding Proteins